Atezolizumab (0, 2.5, 5, 10, 20, and 40 µg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells.
Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway. Atezolizumab (10 µg/ml; 24 hours; HOS and 143B cells) induces autophagy in osteosarcoma cells.